Multigene panel testing, as a regular practice, will likely continue to detect germline variants in other non-BRCA1/2 genes, which are individually rare but confer a modest increase in cancer risk with questionable associated clinical significance (Freitas et al. 2018; Katona et al. 2018). Here, BRCA1 is linked to cancer.